KDR and meningioma: Furthermore, a currently recruiting phase II trial (NCT02847559) and a recently completed phase II trial with pending results (NCT01125046) explored the impact of the VEGFR2 inhibitor bevacizumab in the treatment of patients with recurrent or progressive meningioma.